Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic ArthritisM.H. Otten, Lisette W. A. van Suijlekom‐Smit, Femke H. M. Prince et al.|JAMA|2011Cited by 149
Tumor Necrosis Factor-blocking Agents for Children with Enthesitis-related Arthritis — Data from the Dutch Arthritis and Biologicals in Children Register, 1999–2010M.H. Otten, Lisette W. A. van Suijlekom‐Smit, Femke H. M. Prince et al.|The Journal of Rheumatology|2011Cited by 73
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterM.H. Otten, Lisette W. A. van Suijlekom‐Smit, Janneke Anink et al.|Annals of the Rheumatic Diseases|2012Cited by 59
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterM.H. Otten, Lisette W. A. van Suijlekom‐Smit, Janneke Anink et al.|Annals of the Rheumatic Diseases|2014Cited by 58
Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children RegisterJanneke Anink, Lisette W. A. van Suijlekom‐Smit, Femke H. M. Prince et al.|Lara D. Veeken|2015Cited by 52